Literature DB >> 9035170

Possible person-to-person transmission of Escherichia coli O111--associated hemolytic uremic syndrome.

B Boudailliez1, P Berquin, P Mariani-Kurkdjian, D Ilef, B Cuvelier, I Capek, B Tribout, E Bingen, C Piussan.   

Abstract

Over a 3-month period, ten children (aged 1-13 years) from a 15-km radius in southern Picardy developed typical D+ hemolytic uremic syndrome (HUS). Polymerase chain reaction, using two pairs of verocytotoxin 1-(VT1) and VT2-specific oligonucleotide primers and an internal control was used to detect VT genes directly from stools samples. VT2 gene was detected in seven of nine patients' stools and in 5 of 14 contacts' stool samples. A VT2-producing Escherichia coli (VTEC) O111 was isolated from five of nine children's stools and in 3 adults' stools of the 14 tested. A retrospective case-control study was performed which showed a higher rate of absence in school A, where the first four cases were detected, compared with a control school. The odds ratio for the whole school was 2.77 (confidence interval 1.46-5.26), and 15 (confidence interval 2.54-115.6) if only the nursery classes were considered. A culture of all food samples from households was always negative for VTEC. A retrospective cohort study performed in 89% of children attending school A showed no linkage between food or drink and gastroenteritis. These findings emphasize the potential for person-to-person transmission of VT2-producing E. coli O111, since the only salient risk factor was close contact.

Entities:  

Mesh:

Year:  1997        PMID: 9035170     DOI: 10.1007/s004670050229

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  17 in total

1.  Enteroaggregative, Shiga toxin-producing Escherichia coli O111:H2 associated with an outbreak of hemolytic-uremic syndrome.

Authors:  S Morabito; H Karch; P Mariani-Kurkdjian; H Schmidt; F Minelli; E Bingen; A Caprioli
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

2.  Virulence of the Shiga toxin type 2-expressing Escherichia coli O104:H4 German outbreak isolate in two animal models.

Authors:  Tonia Zangari; Angela R Melton-Celsa; Aruna Panda; Nadia Boisen; Mark A Smith; Ivan Tatarov; Louis J De Tolla; James P Nataro; Alison D O'Brien
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

Review 3.  Epidemiology and clinical manifestations of enteroaggregative Escherichia coli.

Authors:  Betina Hebbelstrup Jensen; Katharina E P Olsen; Carsten Struve; Karen Angeliki Krogfelt; Andreas Munk Petersen
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

Review 4.  Management of acute renal failure.

Authors:  A Bagga
Journal:  Indian J Pediatr       Date:  1999 Mar-Apr       Impact factor: 1.967

5.  Enteroaggregative Shiga toxin-producing Escherichia coli of serotype O104:H4 in Belgium and Luxembourg.

Authors:  K De Rauw; S Vincken; L Garabedian; E Levtchenko; I Hubloue; J Verhaegen; J Craeghs; Y Glupczynski; J Mossong; D Piérard
Journal:  New Microbes New Infect       Date:  2014-08-05

6.  Identification of sequence diversity in the Escherichia coli fliC genes encoding flagellar types H8 and H40 and its use in typing of Shiga toxin-producing E. coli O8, O22, O111, O174, and O179 strains.

Authors:  Lothar Beutin; Eckhard Strauch
Journal:  J Clin Microbiol       Date:  2006-11-29       Impact factor: 5.948

7.  Molecular characterization of a Shiga toxigenic Escherichia coli O113:H21 strain lacking eae responsible for a cluster of cases of hemolytic-uremic syndrome.

Authors:  A W Paton; M C Woodrow; R M Doyle; J A Lanser; J C Paton
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

8.  Virulence properties and characteristics of Shiga toxin-producing Escherichia coli in São Paulo, Brazil, from 1976 through 1999.

Authors:  T M I Vaz; K Irino; M A M F Kato; A M G Dias; T A T Gomes; M I C Medeiros; M M M Rocha; B E C Guth
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

9.  A universal polysaccharide conjugated vaccine against O111 E. coli.

Authors:  Gabrielle R Andrade; Roger R C New; Osvaldo A Sant'Anna; Neil A Williams; Rosely C B Alves; Daniel C Pimenta; Hugo Vigerelli; Bruna S Melo; Letícia B Rocha; Roxane M F Piazza; Lucia Mendonça-Previato; Marta O Domingos
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

10.  Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coli.

Authors:  Susanne Hauswaldt; Martin Nitschke; Friedhelm Sayk; Werner Solbach; Johannes K-M Knobloch
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.